Eli Lilly Q2 2025 Earnings

๐Ÿ“Š Eli Lilly Q2 2025 Earnings: Strong Growth with a Cautionary Note

๐Ÿ—“️ Result Declared: August 7, 2025
Ticker: NYSE: LLY

Eli Lilly reported impressive second-quarter results for 2025, driven by soaring demand for its weight-loss and diabetes treatments. While financial performance exceeded Wall Street expectations, a clinical trial miss in its oral obesity drug tempered investor enthusiasm, causing a drop in share price.

๐Ÿ” Q2 2025 vs Q2 2024: Year-on-Year Financial Comparison

Metric Q2 2025 Q2 2024 YoY Change
Revenue $15.56 billion $11.42 billion +36%
Reported EPS $6.29 $3.28 +92%
Non-GAAP EPS $6.31 $3.92 +61%
Gross Margin (Non-GAAP) 85.0% 79.7% +5.3% pts
Mounjaro Sales ~$5.20 billion ~$3.10 billion +68%
Zepbound Sales ~$3.38 billion ~$1.24 billion +172%
Free Cash Flow $4.12 billion $2.45 billion +68%

๐Ÿš€ Highlights

  • Mounjaro and Zepbound continue to outperform expectations in the diabetes and weight-loss segments.
  • Raised full-year guidance to $60–62 billion in revenue and $21.75–$23.00 in non-GAAP EPS.
  • Orforglipron showed solid but slightly underwhelming results, triggering a stock price dip.

๐Ÿง  Key Insight

Despite stellar financial results, biotech valuations often hinge on drug development outcomes. Investors will closely monitor how Lilly responds to competitive pressures from Novo Nordisk and others in the GLP-1 space.

Disclaimer: This post is for informational purposes only and does not constitute investment advice.

Comments

Popular posts from this blog

NVIDIA Q4 FY2026 Results: Revenue Jumps 73% YoY to $68.1B – Full Financial Summary & Analysis

Can Nasdaq Crash After US Attack on Iran? Market Impact Explained

DoorDash Q4 FY2025 Results: Revenue Soars 38% YoY, Profit Up 51% – Full Financial Breakdown

Upcoming Big Tech Earnings Dates

Berkshire Hathaway Q4 2025 Results: Operating Income Falls 30% YoY – Full Financial Summary